Literature DB >> 12237261

Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.

Jillian G Baker1, Ian P Hall, Stephen J Hill.   

Abstract

1 It has recently been reported that CGP 12177 can act as an agonist at a novel secondary site within the human beta(1)-adrenoceptor. The aim of this study was to undertake a detailed pharmacological study of the effects of CGP 12177 on the human beta(2)-adrenoceptor. 2 CGP 12177 acted as a potent partial agonist of (3)H-cyclic AMP accumulation (log EC(50)-8.90+/-0.06) and CRE-mediated reporter gene transcription (log EC(50)-9.66+/-0.04) in CHO-K1 cells expressing the human beta(2)-adrenoceptor. These CGP-induced responses were antagonized by the beta(2)-selective antagonist ICI 118551 (apparent log K(D) values of -8.84+/-0.15 and -9.51+/-0.02 for the cyclic AMP and reporter gene responses respectively). 3 CGP 12177 was also able to antagonize both cyclic AMP and reporter gene responses to more efficacious beta(2)-agonists with similar log K(D) values (e.g. -9.57+/-0.15 and -10.04+/-0.096 respectively with salbutamol as agonist). 4 (3)H-CGP 12177 binding to beta(2)-adrenoceptors in intact CHO-beta(2) cells yielded a log K(D) value of -9.84+/-0.06, but indicated that the ligand dissociates very slowly from the receptor (t(1/2) for dissociation=65 min). However, studies with a Green Fluorescent Protein (GFP)-tagged beta(2)-adrenoceptor indicated that CGP 12177 does not stimulate beta(2)-adrenoceptor internalization. 5 This study demonstrates that CGP 12177 is a high affinity partial agonist of both cAMP accumulation and CRE-mediated gene transcription at the human beta(2)-adrenoceptor. It provides no evidence that CGP 12177 can discriminate a secondary site on the beta(2)-adrenoceptor analogous to that observed for the human beta(1)-adrenoceptor. However, despite its very weak actions on cAMP accumulation, the potent agonist effects of CGP 12177 on CRE-mediated gene transcription at the human beta(2)-adrenoceptor, coupled with its long duration of action, offers a potential lead for drug development for the treatment of chronic inflammatory airway diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237261      PMCID: PMC1573492          DOI: 10.1038/sj.bjp.0704855

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

Review 1.  Partial agonists and G protein-coupled receptor desensitization.

Authors:  R B Clark; B J Knoll; R Barber
Journal:  Trends Pharmacol Sci       Date:  1999-07       Impact factor: 14.819

2.  Secreted placental alkaline phosphatase as a eukaryotic reporter gene.

Authors:  B R Cullen; M H Malim
Journal:  Methods Enzymol       Date:  1992       Impact factor: 1.600

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Anomalous behavior of CGP 12177A on beta 1-adrenergic receptors.

Authors:  M D Pak; P H Fishman
Journal:  J Recept Signal Transduct Res       Date:  1996 Jan-Mar       Impact factor: 2.092

5.  (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice.

Authors:  A J Kaumann; F Preitner; D Sarsero; P Molenaar; J P Revelli; J P Giacobino
Journal:  Mol Pharmacol       Date:  1998-04       Impact factor: 4.436

6.  Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor.

Authors:  B January; A Seibold; C Allal; B S Whaley; B J Knoll; R H Moore; B F Dickey; R Barber; R B Clark
Journal:  Br J Pharmacol       Date:  1998-02       Impact factor: 8.739

7.  Demonstration of the suitability of CGP 12177 for in vivo studies of beta-adrenoceptors.

Authors:  M P Law
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

8.  (-)-CGP 12177-induced increase of human atrial contraction through a putative third beta-adrenoceptor.

Authors:  A J Kaumann
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

9.  Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor.

Authors:  J McDonnell; M L Latif; E S Rees; N J Bevan; S J Hill
Journal:  Br J Pharmacol       Date:  1998-10       Impact factor: 8.739

10.  Characterization of beta 1- and beta 3-adrenoceptors in intact brown adipocytes of the rat.

Authors:  F D'Allaire; C Atgié; P Mauriège; P M Simard; L J Bukowiecki
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more
  18 in total

1.  Do fluorescent drugs show you more than you wanted to know?

Authors:  J C McGrath; C J Daly
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

2.  The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

Authors:  Jillian G Baker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

3.  The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.

Authors:  Jillian G Baker
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Homology model and docking studies on porcine β₂ adrenoceptor: description of two binding sites.

Authors:  Marvin A Soriano-Ursúa; José Correa-Basurto; José G Trujillo-Ferrara; Alberto J Kaumann
Journal:  J Mol Model       Date:  2011-01-04       Impact factor: 1.810

5.  Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.

Authors:  Jillian G Baker; Richard G W Proudman; Stephen J Hill
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

Review 6.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

7.  A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.

Authors:  Jillian G Baker
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology.

Authors:  Clive J Lewis; Haibin Gong; Morris J Brown; Sian E Harding
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

10.  G-protein-coupled receptors: past, present and future.

Authors:  Stephen J Hill
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.